Life sciences company Revive Therapeutics Ltd. (OTCQB: RVVTF) is advancing its first Phase I/II clinical trial of oral psilocybin for methamphetamine use disorder treatment while also developing an oral psilocybin thin film strip product.

Revive is currently studying psilocybin’s potential as treatment for the addiction of this particular stimulant drug together with the University of Wisconsin-Madison. The Phase I/II clinical trial holds both FDA and the Institutional Review Board approval, and is being …

Full story available on Benzinga.com